Invex rises after neuro drug wins panel nod for late-stage trial in Australia

Invex Therapeutics

30/09/2022 06:55

** Shares of Invex Therapeutics  IXC.AX  rise as much as
5.9% , their highest since Sept. 20
    ** Shares rise as the biopharma co gets a second approval
from the Human Research Ethics Committee to commence late-stage
clinical trials of the neurological drug Presendin in Australia
 urn:newsml:reuters.com:*:nASX6c4D6R
    ** Stock posts its biggest intraday pct gain since Sept 15
    ** Stock on track for 3rd straight month of gains
    ** Stock has fallen 16.3% this year, as of last close
 (Reporting by Rishav Chatterjee in Bengaluru)
 ((Rishav.Chatterjee@thomsonreuters.com;))